Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/05/2790780/0/en/Bolt-Biotherapeutics-Enrolls-First-Patient-in-Phase-2-Clinical-Study-Evaluating-BDC-1001-in-Patients-with-HER2-Positive-Breast-Cancer-Previously-Treated-with-Enhertu.html

REDWOOD CITY, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), as a single agent and in combination with the HER2-targeting antibody pertuzumab.

Read more at globenewswire.com

Related news for (BOLT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.